Literature DB >> 7536268

Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy.

V E Weldon1, F R Tavel, H Neuwirth, R Cohen.   

Abstract

Positive specimen margins and detectable postoperative prostate specific antigen (PSA) levels were analyzed after 200 consecutive radical perineal prostatectomies for clinical stages T1 and T2 adenocarcinoma of the prostate. Clinical parameters that correlated with lymph node metastases in concomitant pelvic lymphadenectomies were also noted. At a mean followup of 35 months 79% of the patients had undetectable PSA levels. Step-section pathological analysis of specimens obtained by either nerve sparing or extended radical modifications revealed that 41% of the tumors were organ confined and 56% had negative margins. Selective sacrifice of the posterolateral periprostatic fascia and the enclosed neurovascular bundle achieved negative margins and undetectable PSA levels despite capsular penetration in 15% of all patients. Of all positive margins with the perineal approach, solitary positive apical and posterolateral margins were infrequent (7% and 16%, respectively) but solitary positive anterior margins were more so (25%). Of those positive anterior margins 41% appeared to be artifactual and 45% might have been eliminated by avoiding avulsion of the puboprostatic ligaments. Pelvic lymphadenectomy could have been eliminated in 58% of the patients (clinical stage T2b or less, biopsy Gleason score 6 or less and PSA level 11 or less, for a node negative predictive value of 99%).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536268

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  [Diagnostics of radical prostatectomy specimens. Results of the 2009 consensus conference of the International Society of Urological Pathology].

Authors:  G Kristiansen; J R Srigley; B Delahunt; L Egevad
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

Review 2.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

3.  The influence of extent of surgical margin positivity on prostate specific antigen recurrence.

Authors:  R E Emerson; M O Koch; T D Jones; J K Daggy; B E Juliar; L Cheng
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Digital versus light microscopy assessment of surgical margin status after radical prostatectomy.

Authors:  Metka Volavšek; Ana Blanca; Rodolfo Montironi; Liang Cheng; Maria R Raspollini; Nuno Vau; Jorge Fonseca; Francesco Pierconti; Antonio Lopez-Beltran
Journal:  Virchows Arch       Date:  2018-02-16       Impact factor: 4.064

5.  Radical perineal prostatectomy: a more optimal treatment approach than laparoscopic radical prostatectomy in obese patients?

Authors:  Albert C Leung; Arnold Melman
Journal:  Rev Urol       Date:  2005

6.  Experience with radical perineal prostatectomy in the treatment of localized prostate cancer.

Authors:  Evi Comploj; Armin Pycha
Journal:  Ther Adv Urol       Date:  2012-06

Review 7.  What's a man to do? Treatment options for localized prostate cancer.

Authors:  Tom Pickles
Journal:  Can Fam Physician       Date:  2004-01       Impact factor: 3.275

Review 8.  Adjuvant radiation therapy after radical prostatectomy: when is it indicated?

Authors:  Stephen M Graham; Jeffrey M Holzbeierlein
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

9.  Iatrogenic and non-iatrogenic positive margins: incidence, site, factors involved, and time to PSA progression following radical prostatectomy.

Authors:  Athanase Billis; Isabela C Watanabe; Matheus V Costa; Gilliat H Telles; Luis A Magna
Journal:  Int Urol Nephrol       Date:  2007-06-30       Impact factor: 2.370

10.  Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy.

Authors:  K W Kwak; H M Lee; H Y Choi
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-06-02       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.